Sir Steve Jackson
University of Cambridge Professor of Biology and Senior Group Leader Cancer Research UK Cambridge Institute.

Before arriving in Cambridge in 1991, Steve carried out four years’ post-doctoral training in the laboratory of Prof. Robert Tjian at UC. Berkeley, USA. Steve’s academic laboratory has played pioneering roles in shaping our understanding of DNA repair processes, and how defects in them give rise to disease. In addition to conceiving Adrestia, Steve founded and served as CSO for the companies Mission Therapeutics and KuDOS Pharmaceuticals, the latter of which developed the blockbuster anti-cancer drug olaparib/Lynparza. Steve is a fellow of the Royal Society and the Academy of Medical Sciences UK, and he has received various national and international awards. Steve received his BSc in Biochemistry from the University of Leeds and his PhD in Molecular Biology from the University of Edinburgh.